Skip to main content
ONCO
NASDAQ Life Sciences

Onconetix Seeks Shareholder Approval for Another Reverse Stock Split to Maintain Nasdaq Listing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.529
Mkt Cap
$1.877M
52W Low
$0.44
52W High
$14.858
52W Position info
20% above low
Off High info
96% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ONCO sits 20% above its 52-week low of $0.44 on light trading volume (0.2× avg).

Summary

Onconetix is seeking shareholder approval for additional reverse stock split authority, a move necessitated by its ongoing failure to meet Nasdaq's minimum bid price requirement, further compounding concerns raised by its recent 'going concern' disclosure.


Key Events · Corporate Governance and Compliance · ONCO

  • New Reverse Stock Split Proposal

    Shareholders will vote on granting the Board discretionary authority to effect one or more reverse stock splits at a ratio of 1-for-2 to 1-for-10, with an aggregate limit of 1-for-100, to be completed within one year.

  • Persistent Nasdaq Non-Compliance

    The company's 30-day trailing closing bid price was below $1.00 as of March 17, 2026, indicating a renewed struggle to meet Nasdaq's minimum bid price rule despite a previous 1-for-85 reverse split in June 2025.

  • Follows Prior Reverse Split Authorization

    This new proposal comes after shareholders already approved a reverse stock split authority (1-for-2 to 1-for-50) on February 3, 2026, which has not yet been implemented, signaling a continuous need for such measures.

  • Context of Going Concern Warning

    This filing closely follows the company's 10-K on March 13, 2026, which disclosed substantial doubt about its ability to continue as a going concern and material weaknesses in internal controls, underscoring the severity of its financial position.


Analysis · ONCO · Life Sciences

Onconetix is requesting shareholder approval for discretionary authority to effect one or more reverse stock splits, ranging from 1-for-2 to 1-for-10, with an aggregate limit of 1-for-100. This proposal comes just five days after the company's 10-K filing disclosed substantial doubt about its ability to continue as a going concern and material weaknesses in internal controls. This marks a continuous struggle for Nasdaq compliance, following a 1-for-85 reverse split in June 2025 and a previously approved (but not yet implemented) reverse split authority in February 2026. The repeated need for reverse splits, despite prior actions, highlights severe underlying financial distress and a persistent inability to maintain its stock price above Nasdaq's minimum bid requirement. This ongoing situation significantly erodes investor confidence and complicates future capital-raising efforts.

At the time of this filing, ONCO was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.44 to $14.86. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ONCO - Latest Insights

ONCO
Jul 07, 2026, 9:01 AM EDT
Filing Type: 425
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.8382 info
Change: -$0.2618 (-24%) info
Market Cap: $3.005M info
ONCO
Jul 07, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.06
Real-time Price: $0.8382 info
Change: -$0.2218 (-21%) info
Market Cap: $3.005M info
ONCO
Jun 24, 2026, 8:31 AM EDT
Filing Type: 425
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.8382 info
Change: -$0.3018 (-26%) info
Market Cap: $3.005M info
ONCO
Jun 17, 2026, 11:24 AM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.02
Real-time Price: $0.8382 info
Change: -$0.1818 (-18%) info
Market Cap: $3.005M info
ONCO
Jun 08, 2026, 5:44 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $1.02
Real-time Price: $0.8382 info
Change: -$0.1818 (-18%) info
Market Cap: $3.005M info